KROS Keros Therapeutics Forecast, Technical & Fundamental Analysis
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs... Show more
KROS is expected to report earnings to rise 15.70% to -139 cents per share on August 12
Q2'26
Est.
$-1.40
Q1'26
Missed
by $0.18
Q4'25
Missed
by $0.16
Q3'25
Beat
by $0.87
Q2'25
Beat
by $0.37
The last earnings report on May 14 showed earnings per share of -121 cents, missing the estimate of -102 cents. With 267.99K shares outstanding, the current market capitalization sits at 217.51M.
A.I. Advisor
published General Information
General Information
a biopharmaceutical company, which focuses on treatments for rare muscle diseases
A.I.dvisor indicates that over the last year, KROS has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then AXON could also see price increases.
KROS's RSI Indicator climbs out of oversold territory
The RSI Oscillator for KROS moved out of oversold territory on May 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 42 similar instances when the indicator left oversold territory. In of the 42 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on KROS as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for KROS just turned positive on June 17, 2026. Looking at past instances where KROS's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in of 291 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
KROS moved below its 50-day moving average on May 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for KROS crossed bearishly below the 50-day moving average on May 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
KROS broke above its upper Bollinger Band on June 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KROS entered a downward trend on June 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.761) is normal, around the industry mean (20.978). P/E Ratio (4.778) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). KROS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (10.753) is also within normal values, averaging (367.072).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. KROS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
